MedCAC Review Of ESAs In Renal Disease To Help Determine Need For NCD
Executive Summary
The Medicare Evidence Development and Coverage Advisory Committee's review of the use of erythropoiesis-stimulating agents in chronic kidney disease is a first step toward determining whether the Centers for Medicare and Medicaid Services should open a national coverage determination process on Medicare payments for such treatment, according to CMS Chief Medical Officer Barry Straube
You may also be interested in...
Maintaining The Status Quo For ESAs: No Medicare NCD in Renal Disease, CMS Proposes
Despite "exhaustive search," CMS has not found the data to set parameters around Medicare coverage for ESAs in the renal setting.
ESA Data On Survival Benefit In Renal Transplant Grafts Are Insufficient - Medicare Panel
The MedCAC review focused narrowly on the benefit of using ESAs - Amgen's Aranesp (darbepoetin alfa) and Centocor Ortho Biotech's Procrit (epoetin alfa) - in transplant graft survival for kidney patients.
ESA Use In Chronic Kidney Disease Will Get Second MedCAC Review
Medicare coverage of Amgen's Aranesp and other erythropoiesis-stimulating agents in chronic kidney disease is the topic for a meeting by the Medicare Evidence Development and Coverage Advisory Committee on Jan. 19.